Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report
暂无分享,去创建一个
[1] R. Flipo,et al. Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study , 2019, Rheumatology and Therapy.
[2] G. Espinosa,et al. TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA , 2017, Retina.
[3] E. Quesada-Masachs,et al. Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis–associated Uveitis , 2017, The Journal of Rheumatology.
[4] A. Heiligenhaus,et al. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis , 2016, The Journal of Rheumatology.
[5] G. Espinosa,et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.
[6] C. Wouters,et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. , 2012, The New England journal of medicine.